Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer

被引：0
|
作者：
Shaotang Li
Pan Dr Chi
机构：
[1] Fujian Medical University,Postgraduate School
[2] Affiliated Union Hospital of Fujian Medical University,Department of Colorectal and Anal Surgery
来源：
BioDrugs | 2011年 / 25卷
关键词：
Overall Survival; Bevacizumab; Irinotecan; Oxaliplatin; Capecitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：43 / 50
页数：7
相关论文
共 50 条
  • [1] Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer Analysis of Multiple Methods
    Li, Shaotang
    Chi, Pan
    [J]. BIODRUGS, 2011, 25 (01) : 43 - 50
  • [2] SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT
    Van Cutsem, E.
    Berry, S.
    Michael, M.
    Kretzschmar, A.
    Rivera, F.
    DiBartolomeo, M.
    Mazier, M.
    Andre, N.
    Cunningham, D.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
  • [3] Optimizing first-line chemotherapy for metastatic colorectal cancer
    Adams, Richard A.
    [J]. COLORECTAL CANCER, 2012, 1 (03) : 241 - 253
  • [4] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    [J]. HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [5] Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis
    Wang Ming
    Zheng Xiaofeng
    Ruan Xiaojiao
    Ye Bailiang
    Cai Long
    Lin Feizhuan
    Tu Jinfu
    Jiang Feizhao
    Li Shaotang
    [J]. CHINESE MEDICAL JOURNAL, 2014, 127 (03) : 538 - 546
  • [6] Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer
    Bai, Long
    Wang, Feng
    Li, Zhe-zhen
    Ren, Chao
    Zhang, Dong-sheng
    Zhao, Qi
    Lu, Yun-xin
    Wang, De-shen
    Ju, Huai-qiang
    Qiu, Miao-zhen
    Wang, Zhi-qiang
    Wang, Feng-hua
    Xu, Rui-hua
    [J]. MEDICINE, 2016, 95 (51) : e4531
  • [7] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
  • [8] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    [J]. ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [9] Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab
    Bousahba, A.
    Behourah, Z.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [10] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
12345